Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts Sells 600 Shares

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $244.49, for a total transaction of $146,694.00. Following the completion of the sale, the executive vice president now owns 63,444 shares of the company’s stock, valued at $15,511,423.56. The trade was a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Johanna Roberts also recently made the following trade(s):

• On Monday, November 18th, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $239.74, for a total transaction of $143,844.00.
• On Tuesday, October 1st, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $190.76, for a total transaction of $114,456.00.

Penumbra Stock Up 0.2 %

NYSE:PEN traded up $0.40 during mid-day trading on Tuesday, hitting $245.24. 279,206 shares of the company’s stock were exchanged, compared to its average volume of 378,372. The business has a fifty day moving average price of $218.84 and a 200 day moving average price of $199.03. The company has a market cap of $9.41 billion, a PE ratio of 285.16, a P/E/G ratio of 2.46 and a beta of 0.51. Penumbra, Inc. has a one year low of $148.00 and a one year high of $277.34. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.82 and a quick ratio of 3.25.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.16. Penumbra had a net margin of 2.97% and a return on equity of 8.99%. The company had revenue of $301.04 million during the quarter, compared to the consensus estimate of $297.36 million. During the same quarter last year, the firm earned $0.67 earnings per share. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. Equities analysts predict that Penumbra, Inc. will post 2.81 EPS for the current year.

Penumbra announced that its Board of Directors has authorized a share repurchase plan on Tuesday, August 13th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to purchase up to 2.6% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its shares are undervalued.

Hedge Funds Weigh In On Penumbra

Several institutional investors have recently made changes to their positions in PEN. Tidal Investments LLC grew its stake in shares of Penumbra by 276.9% during the 1st quarter. Tidal Investments LLC now owns 4,971 shares of the company’s stock valued at $1,109,000 after acquiring an additional 3,652 shares during the period. CWM LLC lifted its holdings in Penumbra by 215.7% during the second quarter. CWM LLC now owns 1,550 shares of the company’s stock valued at $279,000 after purchasing an additional 1,059 shares in the last quarter. Linden Thomas Advisory Services LLC boosted its position in shares of Penumbra by 98.2% in the second quarter. Linden Thomas Advisory Services LLC now owns 11,474 shares of the company’s stock worth $2,065,000 after purchasing an additional 5,686 shares during the period. Canandaigua National Bank & Trust Co. bought a new stake in shares of Penumbra during the 2nd quarter valued at $258,000. Finally, SG Americas Securities LLC purchased a new position in shares of Penumbra in the second quarter valued at about $1,586,000. Institutional investors own 88.88% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Truist Financial increased their target price on shares of Penumbra from $200.00 to $235.00 and gave the company a “buy” rating in a report on Monday, October 14th. Needham & Company LLC reissued a “hold” rating on shares of Penumbra in a research report on Thursday, October 31st. Robert W. Baird upped their target price on Penumbra from $244.00 to $248.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Leerink Partnrs raised shares of Penumbra to a “strong-buy” rating in a research report on Tuesday, September 3rd. Finally, Royal Bank of Canada raised their target price on Penumbra from $205.00 to $222.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Five equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Penumbra presently has a consensus rating of “Moderate Buy” and an average price target of $230.92.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.